Cardiol Therapeutics (TSE:CRDL) Trading Down 14.6% – Here’s What Happened

Cardiol Therapeutics Inc. (TSE:CRDL) dropped 14.6% during mid-day trading on Tuesday . The company traded as low as C$1.24 and last traded at C$1.29. Approximately 551,069 shares were traded during mid-day trading, an increase of 405% from the average daily volume of 109,045 shares. The stock had previously closed at C$1.51.

Cardiol Therapeutics Stock Performance

The company has a market cap of C$129.00 million, a P/E ratio of -3.15 and a beta of 1.31. The firm has a 50 day moving average of C$1.50 and a 200-day moving average of C$1.64. The company has a quick ratio of 6.84, a current ratio of 2.49 and a debt-to-equity ratio of 1.59.

Cardiol Therapeutics (TSE:CRDL) last issued its earnings results on Thursday, November 13th. The company reported C($0.12) earnings per share for the quarter. As a group, sell-side analysts anticipate that Cardiol Therapeutics Inc. will post -0.49 EPS for the current fiscal year.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company’s lead drug candidate, CardiolRxTM (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease.